Skip to main content

Table 3 The mean weight for every criterion

From: Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors

 

Mean

SD

Disease severity

3.58

0.75

Size of affected population

3.58

0.75

Unmet needs

3.01

0.55

Comparative effectiveness

3.73

0.82

Comparative safety/tolerability

3.58

0.98

Comparative patient-perceived health / PRO

3.44

0.63

Type of therapeutic benefit

3.58

1.17

Comparative cost consequences – cost of intervention

3.58

0.75

Comparative cost consequences – other medical costs

3.30

0.98

Comparative cost consequences – non-medical costs

2.87

1.03

Quality of evidence

4.01

0.52

Expert consensus/clinical practice guidelines

3.44

0.63